BIS Sets Standard For Medical Devices, Health Informatics-Related Products

New Delhi : The Bureau of Indian Standards (BIS) has notified Indian standards for various medical devices and health informatics-related products and processes as part of its efforts to set standards including for medication related processes and electronic prescriptions, among others.

BIS has fixed prices for various health informatics-related devices and infrastructure, including dynamic on-demand virtual private network for health information infrastructure (IS 17762:2022/ISO/TR 11636: 2009), provisions for health applications on mobile/smart devices (IS 17763:2022/ISO/TR 17522:2015), requirements for record of a dispense of a medicinal product (IS17764: 2022/ISO/TS 19293: 2018), personal health data generated on a daily basis (IS 17765: 2022/ISO/TR 21835: 2020), business requirements for a syntax to exchange structured dose information for medicinal products (IS 17767: 2022/ISO/TS 17251: 2016), requirements for a knowledge base for clinical decision support systems to be used in medication-related processes (IS 17768: 2022/ISO/TS 22756: 2020), requirements for electronic prescriptions (IS 17769:2022/ISO 17523: 2016).

The other standards for the health informatics-related processes and products include medication management concepts and definitions (iS 17770: 2022/ISO/TR 20831: 2017), representation of categorical structures of terminology [CatStructure] (IS 17771: 2022/ISO 17115: 2020), guidelines on data protection to facilitate trans-border flows of personal health data (IS 17797: 2022/ISO 22857: 2013), and data elements and their metadata for describing structured clinical genomic sequence information in electronic health records (IS 17798: 2022/ISO/TS 20428: 2017). These standards have a date of establishment fixed as February 11, 2022, it added.

Through another  notification dated February 15, it has set IS 17709: 2022/ISO 11318:2002 standard for cardiac defibrillators – connector assembly DF-1 for implantable defibrillators, its dimensions and test requirements.

Under Cardiovascular Implants and Extracorporeal Systems, vascular device-drug combination products, as per Part 2 of local regulatory information, have been set with IS 17751 (Part 2): 2022/ISO/TR 12417-2 : 2017 standards.

For Underpad, a medical textiles product, it has set IS 17786: 2022 standards. All these standards were established as on February 10, 2022, said the notification.

It has also set the IS/ISO 10993-18: 2020 standard for biological evaluation of medical devices – chemical characterisation of medical device materials within a risk management process.

  • Related Posts

    Dr Reddy’s delays semaglutide supplies due to API issue

    MUMBAI: Dr Reddy’s Laboratories’ plans to capitalize on the early generic semaglutide market have hit a setback after manufacturing issues delayed supplies of the blockbuster diabetes and weight-loss drug, forcing…

    India Tightens Rules On Alcohol-Containing Medicines

    New rules on alcohol in medicine: The Centre has brought oral medicines containing more than 12% ethyl alcohol and sold in bottles larger than 30 ml under Schedule H1 In…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Dr Reddy’s delays semaglutide supplies due to API issue

    Dr Reddy’s delays semaglutide supplies due to API issue

    India Tightens Rules On Alcohol-Containing Medicines

    India Tightens Rules On Alcohol-Containing Medicines

    One more held in spurious plasma racket; police say he supplied 12 boxes

    One more held in spurious plasma racket; police say he supplied 12 boxes

    Wegovy, Ozempic regain weight as Indian generics fall behind

    Wegovy, Ozempic regain weight as Indian generics fall behind

    Drug regulator orders fresh safety labels for five common antimicrobials

    Drug regulator orders fresh safety labels for five common antimicrobials

    Rajasthan recalls labour-inducing drug after quality test failure

    Rajasthan recalls labour-inducing drug after quality test failure